Suramin sodium salt 

Suramin is a polysulfonated naphthylurea anticancer agent that inhibits tumor cell proliferation. It inhibits the activity of topoisomerase II by blocking the binding of the enzyme to DNA. It's antiangiogenic activity may be related to its ability to bind to and inhibit the activity of several growth factors, including FGFa, FGFb, and PGDF. It uncouples G-proteins from receptors. It is an broad spectrum antagonist at P2X and P2Y purinergic receptors. Suramin has well documented antiprotozoal and anthelmintic activity.

≥95%

H₂O: >10 mg/mL

human ... EGF(1950), P2RX1(5023), P2RY1(5028), PDGFA(5154), PLD1(5337)

von Kugelgen, I., Suramin disrupts receptor-G protein coupling by blocking association of G protein α and β/γ subunits. Pharmacol. Ther. 110, 415-432, (2006)

Chung, W.C., and Kermode, J.C., Suramin disrupts receptor-G protein coupling by blocking association of G protein α and β/γ subunits. J. Pharmacol. Exp. Ther. 313, 191-198, (2005)

Larsen, A.K., et al., Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol. Ther. 99, 167-181, (2003)

Kathir, K.M., et al., Understanding the mechanism of the antimitogenic activity of suramin. Biochemistry 45, 899-906, (2006)

Raj. P.A., et al., Conformational requirements of suramin to target angiogenic growth factors. Angiogenesis 2, 183-199, (1998)

Jacobson, K.A., et al., Molecular recognition at purine and pyrimidine nucleotide (P2) receptors. Curr. Top. Med. Chem 4, 805-819, (2004)

Merck 13,9096

3

QM7000000